- Home
- DC vs TIL Comparison
DC vs TIL Comparison
Compare DC & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DC
- TIL
- Stock Information
- Founded
- DC 2017
- TIL 2018
- Country
- DC United States
- TIL United States
- Employees
- DC N/A
- TIL N/A
- Industry
- DC Precious Metals
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- DC Basic Materials
- TIL Health Care
- Exchange
- DC Nasdaq
- TIL Nasdaq
- Market Cap
- DC 209.6M
- TIL 171.7M
- IPO Year
- DC N/A
- TIL 2021
- Fundamental
- Price
- DC $3.32
- TIL $22.12
- Analyst Decision
- DC Buy
- TIL Strong Buy
- Analyst Count
- DC 1
- TIL 4
- Target Price
- DC $7.50
- TIL $114.00
- AVG Volume (30 Days)
- DC 454.9K
- TIL 83.9K
- Earning Date
- DC 03-27-2025
- TIL 03-20-2025
- Dividend Yield
- DC N/A
- TIL N/A
- EPS Growth
- DC N/A
- TIL N/A
- EPS
- DC N/A
- TIL N/A
- Revenue
- DC N/A
- TIL N/A
- Revenue This Year
- DC N/A
- TIL N/A
- Revenue Next Year
- DC N/A
- TIL N/A
- P/E Ratio
- DC N/A
- TIL N/A
- Revenue Growth
- DC N/A
- TIL N/A
- 52 Week Low
- DC $1.84
- TIL $9.62
- 52 Week High
- DC $3.50
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- DC 67.37
- TIL 48.67
- Support Level
- DC $3.00
- TIL $19.00
- Resistance Level
- DC $3.50
- TIL $25.80
- Average True Range (ATR)
- DC 0.20
- TIL 2.19
- MACD
- DC 0.06
- TIL 0.22
- Stochastic Oscillator
- DC 86.05
- TIL 45.88
About DC Dakota Gold Corp.
Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota. Dakota Gold has high-caliber gold mineral properties covering over 48 thousand acres surrounding the historic Homestake Mine.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.